Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Loargys Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Loargys (pegzilarginase-nbln) — Continuation of Therapy

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Loargys under the medical benefit for MassHealth UPPL members with Arginase 1 Deficiency, including documentation, clinical eligibility, continuation, dosing, and authorization-duration requirements.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyLoargys (pegzilarginase-nbln) — Continuation of Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation through the MassHealth UPPL medical benefit for Loargys coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥2 yearsMinimum member age
    ≥250 μmol/LBaseline arginine threshold
    <200 μmol/LContinuation arginine threshold
    6 monthsInitial authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Reauthorization
    MedicalBenefit

    Coverage Criteria

    New-to-plan current treatment

    Coverage may be considered for a member new to the plan when current treatment is documented.

    New-to-plan continuation pathway: The member's coverage effective date is less than or equal to 90 days, and medical records document that the member is currently receiving the requested drug.Coverage effective date ≤90 days

    Treatment obtained as samples or through a manufacturer's patient assistance program is excluded from this pathway.

    Loargys authorization criteria

    Authorization may be granted when all of the following criteria are met.

    • The member has a diagnosis of Arginase 1 Deficiency (ARG1-D).
    • The member is at least 2 years of age.Age ≥2 years
    • The prescriber is a specialist in genetic or metabolic diseases, or consultation notes from a specialist are provided.
    • ONE of

      • Genetic testing confirms a mutation in the ARG1 gene.
      • Laboratory testing confirms reduced erythrocyte arginase activity.
    • The baseline or pretreatment plasma arginine level is at least 250 μmol/L when applicable.Plasma arginine ≥250 μmol/L; dated within the last 90 days if treatment-naïve
    • The requested agent will be used in combination with a low-protein, arginine-restricted diet.
    • The member's current weight is provided.

      Use the current weight to verify correct dosing.

    • Dosing is appropriate.

    Continuation therapy

    Continuation of therapy requires submission of medical records for all of the following.

    Continuation therapy criteria

    • The member's plasma arginine level is below 200 μmol/L.Plasma arginine <200 μmol/L
    • The member's current weight is documented.
    • Dosing is appropriate.

    For members new to the plan, treatment obtained as samples or through a manufacturer’s patient assistance program is excluded from the new-to-plan current-treatment pathway.

    Clinical Thresholds

    Baseline or Pretreatment Plasma Arginine
    TestBaseline or pretreatment plasma arginine level
    Required level≥250 μmol/L
    Treatment-naïve timingDated within the last 90 days if treatment-naïve
    Continuation Plasma Arginine
    TestContinuation plasma arginine level
    Required level< 200 μmol/L
    UseRequired for continuation of therapy

    Prior Authorization and Documentation

    Prior Authorization

    Medical Benefit Prior Authorization Required

    Prior authorization is required for Loargys (pegzilarginase-nbln) under the MassHealth UPPL medical benefit. Contact Medical Benefit Pharmacy at 833-895-2611 or fax 888-656-6671. Loargys is also available under the pharmacy benefit; consult the MassHealth Drug List for coverage and criteria.

    • Additional agents in this class are available through the pharmacy benefit; consult the MassHealth Drug List for coverage and criteria.
    • Pharmacy Benefit contact: 800-711-4555; fax 844-403-1029.
    Documentation Required

    Submit Current Treatment Records

    For members whose coverage became effective within the last 90 days, submit medical records documenting that the member is currently receiving treatment with the requested drug.

    • Do not use samples or manufacturer patient assistance program access as evidence of current treatment.

    About Loargys

    Loargys (pegzilarginase-nbln) is an arginine-specific enzyme indicated for the treatment of hyperargininemia in adults and children aged 2 years and older with Arginase 1 Deficiency. It is used together with dietary protein restriction.

    Key Clinical Definition

    ARG1-D
    ConditionArginase 1 Deficiency (ARG1-D), a disorder associated with hyperarginemia
    Genetic confirmationGenetic testing confirms a mutation in the ARG1 gene
    Laboratory confirmationLaboratory testing confirms reduced erythrocyte arginase activity

    Initial Loargys Authorization

    Initial Loargys authorization

    Authorization may be granted when all of the following criteria are met.

    Initial authorization criteria

    • The member has a diagnosis of Arginase 1 Deficiency (ARG1-D).
    • The member is at least 2 years of age.Age ≥2 years
    • The prescriber is a specialist in genetic or metabolic diseases, or consultation notes from a specialist are provided.
    • ONE of

      • Genetic testing confirms a mutation in the ARG1 gene.

    Continuation of Therapy

    Continuation of Therapy

    Submission of medical records for ALL of the following:

    Continuation of Loargys

    • The member's plasma arginine level is below 200 μmol/L.Plasma arginine <200 μmol/L
    • The member's current weight is documented.
    • Dosing is appropriate.

    New-to-plan continuation

    For members new to the plan, documentation of current treatment may support continuation coverage.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyLoargys (pegzilarginase-nbln) — Continuation of Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 4, 202746d
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation through the MassHealth UPPL medical benefit for Loargys coverage.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsPrior Authorization and DocumentationAbout LoargysKey Clinical DefinitionInitial Loargys AuthorizationContinuation of Therapy
    Documentation Required

    Initial Authorization Documentation

    For initial authorization, submit documentation supporting the diagnosis, age, specialist involvement, confirmatory testing, and all other applicable clinical requirements.

    • Diagnosis of Arginase 1 Deficiency (ARG1-D).
    • Member is ≥ 2 years of age.
    • Prescriber is a specialist in genetic or metabolic diseases, or provide consultation notes from a specialist.
    • Provide medical records or testing showing either a mutation in the ARG1 gene or reduced erythrocyte arginase activity.
    • For treatment-naïve members, provide a baseline/pretreatment plasma arginine level of ≥250 μmol/L, dated within the last 90 days.
    • Document use with a low-protein, arginine-restricted diet.
    • Submit the member’s current weight to verify dosing and document appropriate dosing.
    Documentation Required

    Reauthorization Documentation

    For reauthorization, submit current clinical and dosing information demonstrating that continuation requirements are met.

    • Plasma arginine level < 200 μmol/L.
    • Member’s current weight.
    • Appropriate dosing.
    Denial Risk

    Insufficient Evidence of Current Treatment

    New-to-plan members may face denial or documentation risk when records do not show ongoing treatment with the requested drug. Coverage effective for ≤ 90 days requires submission of current treatment records.

    • Evidence based only on samples or manufacturer patient assistance programs does not satisfy the current-treatment documentation requirement.
    Denial Risk

    Clinical Criteria Not Met

    Initial authorization may be denied when the clinical criteria are not met or supporting documentation is incomplete.

    • ARG1-D diagnosis is not established.
    • Member is younger than 2 years of age.
    • Prescriber is not a genetic or metabolic disease specialist and specialist consultation notes are not provided.
    • Required confirmatory genetic or laboratory testing is not submitted.
    • Applicable baseline plasma arginine, diet, weight, or dosing requirements are not documented.
    Denial Risk

    Continuation Requirements Not Met

    Continuation may be denied when required laboratory results, current weight, or dosing documentation is missing or does not meet the plan’s criteria.

    • Plasma arginine level is not < 200 μmol/L.
    • Current weight is not submitted.
    • Requested dosing is not appropriate or cannot be verified.
  1. Laboratory testing confirms reduced erythrocyte arginase activity.
  2. The baseline or pretreatment plasma arginine level is at least 250 μmol/L when applicable.Plasma arginine ≥250 μmol/L; dated within the last 90 days if treatment-naïve
  3. The requested agent will be used in combination with a low-protein, arginine-restricted diet.
  4. The member's current weight is provided.

    Use the current weight to verify correct dosing.

  5. Dosing is appropriate.
  6. New-to-plan treatment continuation: The member's coverage effective date is less than or equal to 90 days, and medical records document that the member is currently receiving the requested drug.Coverage effective date ≤90 days

    Treatment obtained as samples or through a manufacturer's patient assistance program is excluded from this pathway.